BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27160286)

  • 1. A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
    Li J; Yu Q; Fu S; Xu M; Zhang T; Xie C; Feng J; Chen J; Zang A; Cai Y; Fu Q; Liu S; Zhang M; Hong Q; Huang L; Yuan X
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1621-8. PubMed ID: 27160286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
    Ferraldeschi R; Minchell LJ; Roberts SA; Tobi S; Hadfield KD; Blackhall FH; Mullamitha S; Wilson G; Valle J; Saunders M; Newman WG
    Pharmacogenomics; 2009 May; 10(5):733-9. PubMed ID: 19450125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
    Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
    Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
    Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
    Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
    Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
    World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
    Fakih MG; Ross ME; Starostik P
    Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
    Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
    Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
    de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
    Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Candamio S; Vidal Y; Mosquera A; Giraldez JM; Lopez R; Carracedo A; Barros F
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1591-9. PubMed ID: 22535333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 13. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
    Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
    Shulman K; Cohen I; Barnett-Griness O; Kuten A; Gruber SB; Lejbkowicz F; Rennert G
    Cancer; 2011 Jul; 117(14):3156-62. PubMed ID: 21287524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
    Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
    Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
    Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
    Biason P; Masier S; Toffoli G
    J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
    Peng H; Duan Z; Pan D; Wen J; Wei X
    Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
    Yan L; Wang XF; Wei LM; Nie YL; Liu JY; Zhang LR
    Int J Clin Pharmacol Ther; 2016 Mar; 54(3):193-9. PubMed ID: 26857783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
    Hu ZY; Yu Q; Zhao YS
    Eur J Cancer; 2010 Jul; 46(10):1856-65. PubMed ID: 20335017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.